LBA 01 - Special Session - Late-Breaking Abstracts

Moderator(s)

• 

  Beth Beadle, MD, PhD, FASTRO

  Stanford University
  Stanford, California, United States
• 

  Rachel Jimenez, MD

  Massachusetts General Hospital
  Boston, MA

Presentations:

• 2:30 PM – 2:40 PM ET

  Outcomes and Immune Responses from INNATE: A Randomized Phase II Trial of Sotigalimab Immunotherapy during Neoadjuvant Therapy of Rectal Cancer
  

  Presenter: Todd Aguilera, MD, PhD – UT Southwestern Medical Center
• 2:40 PM – 2:50 PM ET

  Neoadjuvant Chemoradiation (CROSS) vs. Perioperative Chemotherapy (FLOT) in Esophageal Adenocarcinoma (EAC): ESOPEC - A Randomized Controlled Prospective Multicenter Phase III Trial
  

  Presenter: Thomas Brunner, MD – Medical University Graz
• 2:50 PM – 3:00 PM ET

  Outcomes of RAdium-223 and SABR vs. SABR for oligomEtastatic prostate caNcerS - The RAVENS Phase II Randomized Trial
  

  Presenter: Ana Kiess, MD, PhD – Johns Hopkins University
• 3:00 PM – 3:10 PM ET

  A Phase II Single Arm Trial of Elective Volume Adjusted De-Escalation Radiotherapy (EVADER) in Patients with Low-risk HPV-related Oropharyngeal Squamous Cell Carcinoma
  

  Presenter: Scott Bratman, MD, PhD – Princess Margaret Hospital
• 3:10 PM – 3:20 PM ET

  Radiotherapy Target Volume Delineation Based on Post-Induction Chemotherapy Gross Tumor Volume vs. Pre-induction Volume for Locoregionally Advanced Nasopharyngeal Carcinoma: An Open-Label, Non-Inferio
  

  Presenter: Linglong Tang, MD, PhD – Sun Yat-Sen University Cancer Center
• 3:20 PM – 3:30 PM ET

  Safety Profile of Durvalumab (D) as Consolidation Treatment (tx) in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) in ADRIATIC: Focus on Pneumonitis and Immune-Mediated Adverse Events (imAEs)
  

  Presenter: Puneeth Iyengar, MD, PhD – Memorial Sloan Kettering Cancer Center
• 3:30 PM – 3:40 PM ET

  Neurocognitive Outcome of Conformal Whole Brain Radiotherapy with Bilateral or Unilateral Hippocampal Avoidance Plus Memantine for Brain Metastases: A Phase II Single Blind Randomized Trial
  

  Presenter: Feng-Ming Hsu, MD, PhD – National Taiwan University Hospital